Daiichi Sankyo is the second largest pharma company in Japan, developing small molecules & biologics for various diseases and was came into existence in 2005, through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.
- In Sep 2014, Daiichi acquired Ambit Biosciencs in approx. $ 410 Mn. Ambit was having Quizartinib, a PhIII ready Acute Myeloid Leukemia targeting drug in its pipeline.
- In Apr 2011, Daiichi Sankyo acquired American pharma Plexxikon Inc. in $805 Mn USD with an additional $130 Mn USD in milestone payments. Plexxikon now operates as its wholly owned subsidiary.
- In 2008, Daiichi acquired German biotech company U3 Pharma (developing anti-HER3 mAb against cancer) for $235 Mn USD.
Page 1 of 3
